

# There is another way

## Utilising ADCs to improve outcomes in patients with triple-negative and HR+/HER2-negative mBC

Wednesday, 14 May 2025 | 18:15–19:15 CEST

Room 5, ICM – International Congress Center Messe München,  
Munich, Germany

### AGENDA

18:15–18:20

**Welcome and introduction**



**Dr Hope S. Rugo (US)**

Professor of Medicine and Winterhof Family Professor  
of Breast Oncology, UCSF Helen Diller Family  
Comprehensive Cancer Center, San Francisco, US

18:20–18:35

**ADCs as a treatment option in  
previously treated triple-negative  
and HR+/HER2-negative mBC**



**Dr Hope S. Rugo (US)**

Professor of Medicine and Winterhof Family Professor  
of Breast Oncology, UCSF Helen Diller Family  
Comprehensive Cancer Center, San Francisco, US

18:35–18:55

**Optimising treatment outcomes with  
ADCs in previously treated mTNBC  
and HR+/HER2-negative mBC**



**Prof. Frederik Marmé (Germany)**

Gynaecologic Oncologist, Medical Faculty Mannheim  
Heidelberg University, Mannheim, Germany

18:55–19:10

**Exploring ADCs as treatment options  
in earlier lines of mBC**



**Prof. Rebecca Dent (Singapore)**

Senior Consultant, National Cancer Centre Singapore,  
Singapore, Singapore

19:10–19:15

**Q&A**

All speakers – facilitated by the Chair  
Dr Hope S. Rugo (US)



Oncology

ADCs, antibody-drug conjugates; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; mBC, metastatic breast cancer; mTNBC, metastatic triple-negative breast cancer.

This symposium is sponsored and organised by Gilead and intended for healthcare professionals only.

The purpose of this symposium is scientific exchange. The audience is encouraged to actively participate in the discussion throughout the symposium after each presentation via the voting system and live during the Q&A.

GILEAD and the GILEAD logo are trade marks of Gilead Sciences, Inc. © 2025 Gilead Sciences, Inc. All rights reserved.

February 2025 | GFM-UNB-0058